Li Yi-Fan, Chen Ze-Wen, Xie Zhao-Feng, Wang Shu-Shui, Xie Yu-Mei, Zhang Zhi-Wei
Department of Pediatric Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510100 Guangzhou, Guangdong, China.
Department of Cardiac Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510100 Guangzhou, Guangdong, China.
Rev Cardiovasc Med. 2024 May 8;25(5):159. doi: 10.31083/j.rcm2505159. eCollection 2024 May.
Atrial septal defect (ASD) is the third most common type of structural congenital heart defect. Patent foramen ovale (PFO) is an anatomical anomaly in up to 25% of the general population. With the innovation of occlusion devices and improvement of transcatheter techniques, percutaneous closure has become a first-line therapeutic alternative for treatment of ASD and PFO. During the past few decades, the development of biodegradable occlusion devices has become a promising direction for transcatheter closure of ASD/PFO due to their biodegradability and improved biocompatibility. The purpose of this review is to comprehensively summarize biodegradable ASD/PFO occlusion devices, regarding device design, materials, biodegradability, and evaluation of animal or clinical experiments (if available). The current challenges and the research direction for the development of biodegradable occluders for congenital heart defects are also discussed.
房间隔缺损（ASD）是结构性先天性心脏病的第三大常见类型。卵圆孔未闭（PFO）在高达25%的普通人群中是一种解剖学异常。随着封堵装置的创新和经导管技术的改进，经皮封堵已成为治疗ASD和PFO的一线治疗选择。在过去几十年中，可生物降解封堵装置的发展因其生物可降解性和改善的生物相容性，已成为ASD/PFO经导管封堵的一个有前景的方向。本综述的目的是全面总结可生物降解的ASD/PFO封堵装置，涉及装置设计、材料、生物可降解性以及动物或临床实验评估（如可用）。还讨论了先天性心脏病可生物降解封堵器开发的当前挑战和研究方向。
